Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02128958 · ClinicalTrials.gov registry record · Phase 2
Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
A Phase 2 study, sponsored by Can-Fite BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT02128958 is a Phase 2 study that has completed, run by Can-Fite BioPharma. The registered enrollment target is 78 participants.
The verdict
NCT02128958, a Phase 2 study, has completed, sponsored by Can-Fite BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with advanced HCC and CPB cirrhosis whose disease has progressed while taking 1 prior systemic drug therapy for HCC.
Interventions
- DRUG Placebo
- DRUG CF102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2014-09 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02128958
The ClinicalTrials.gov registry entry for NCT02128958 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Can-Fite BioPharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02128958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02128958 about?
NCT02128958 is a clinical study titled "Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)". This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with advanced HCC and CPB cirrhosis whose disease has progressed while taking 1 prior systemic drug therapy for HCC.
What is the current status of trial NCT02128958?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2014-09. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT02128958?
The interventions under investigation include: Placebo (DRUG), CF102 (DRUG).
Who is sponsoring clinical trial NCT02128958?
This trial is sponsored by Can-Fite BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.